FDA says RoyceDerm LLC marketed Herpes Relief Cream, an unapproved new drug, for herpes symptoms on its website.
What happened
FDA reviewed RoyceDerm's website https://roycederm.com/ in July 2026. It found the product "Herpes Relief Cream" labeled to relieve herpes symptoms, rashes or blisters, redness, and pain, with before-and-after images. FDA concluded the product is an unapproved new drug because no approved application is in effect for it.
What FDA found
Herpes Relief Cream is a drug because its labeling says it is intended to treat herpes symptoms.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)It is a new drug because it is not generally recognized as safe and effective for its labeled use.
FD&C Act section 201(p), 21 U.S.C. 321(p)No FDA-approved application is in effect, so selling it violates the unapproved new drug rules.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA asks RoyceDerm to send a written response to FDAAdvisory@fda.hhs.gov within 15 business days. The response should include corrective steps, steps to prevent recurrence, related documents, and reference number 734781.
Who should pay attention
- online sellers of health products
- companies marketing herpes or STI creams
- regulatory staff reviewing website claims for OTC drugs
This is a summary. Read the original letter on fda.gov.